Fintel reports that on January 5, 2026, William Blair initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Outperform recommendation.
Analyst Price Forecast Suggests 142.82% Upside
As of December 21, 2025, the average one-year price target for Compass Therapeutics is $12.55/share. The forecasts range from a low of $7.07 to a high of $31.50. The average price target represents an increase of 142.82% from its latest reported closing price of $5.17 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Compass Therapeutics is 94MM, an increase of ∞%. The projected annual non-GAAP EPS is -0.36.
What is the Fund Sentiment?
There are 229 funds or institutions reporting positions in Compass Therapeutics. This is an increase of 20 owner(s) or 9.57% in the last quarter. Average portfolio weight of all funds dedicated to CMPX is 0.16%, an increase of 16.55%. Total shares owned by institutions increased in the last three months by 37.11% to 157,676K shares. 
The put/call ratio of CMPX is 0.02, indicating a bullish outlook.
What are Other Shareholders Doing?
Tang Capital Management holds 16,812K shares representing 9.45% ownership of the company. In its prior filing, the firm reported owning 13,496K shares , representing an increase of 19.72%. The firm increased its portfolio allocation in CMPX by 27.70% over the last quarter.
Orbimed Advisors holds 15,220K shares representing 8.56% ownership of the company. No change in the last quarter.
Suvretta Capital Management holds 14,101K shares representing 7.93% ownership of the company. In its prior filing, the firm reported owning 7,149K shares , representing an increase of 49.30%. The firm increased its portfolio allocation in CMPX by 125.44% over the last quarter.
Blackstone Group holds 9,840K shares representing 5.53% ownership of the company. In its prior filing, the firm reported owning 10,025K shares , representing a decrease of 1.88%. The firm decreased its portfolio allocation in CMPX by 9.12% over the last quarter.
Vivo Capital holds 9,545K shares representing 5.37% ownership of the company. In its prior filing, the firm reported owning 6,043K shares , representing an increase of 36.69%. The firm increased its portfolio allocation in CMPX by 67.18% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
